Tg Therapeutics Inc SEC Filings

TGTX NASDAQ

Welcome to our dedicated page for Tg Therapeutics SEC filings (Ticker: TGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking FDA approvals, clinical trial results, and commercialization milestones within TG Therapeutics’ SEC disclosures can feel like decoding a pharmacology textbook. Each 10-K details complex B-cell science, while surprise 8-K releases announce trial outcomes that may move the stock overnight. If you have ever asked “Where can I find TG Therapeutics’ quarterly earnings report?” or wondered how insider trades align with fresh multiple-sclerosis data, you know the challenge.

Stock Titan solves it. Our platform transforms TG Therapeutics SEC filings explained simply into concise, AI-powered insights. Receive alerts the moment a TG Therapeutics 8-K material events explained hits EDGAR, skim AI summaries that translate scientific jargon, and dive deeper when you need original text. We surface what matters in every document: revenue from BRIUMVI launches inside the TG Therapeutics quarterly earnings report 10-Q filing, pipeline risk factors from the TG Therapeutics annual report 10-K simplified, and board pay details extracted from the TG Therapeutics proxy statement executive compensation.

Use cases include:

Monitor TG Therapeutics insider trading Form 4 transactions and receive TG Therapeutics Form 4 insider transactions real-time alerts before market open.
Run instant TG Therapeutics earnings report filing analysis to compare R&D spend versus prior quarters.
Quickly answer client questions with understanding TG Therapeutics SEC documents with AI—no biomedical PhD required.
Track TG Therapeutics executive stock transactions Form 4 around pivotal data readouts.

Whether you’re an analyst modeling cash burn, a portfolio manager gauging sentiment, or a healthcare banker scanning deal clauses, our real-time updates and expert commentary turn dense disclosures into actionable knowledge.

08/04/2025 07:35 AM

Filing

[8-K] TG Therapeutics, Inc. Reports Material Event

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Tg Therapeutics (TGTX)?

The current stock price of Tg Therapeutics (TGTX) is $28.72 as of August 4, 2025.

What is the market cap of Tg Therapeutics (TGTX)?

The market cap of Tg Therapeutics (TGTX) is approximately 5.6B.

What is TG Therapeutics Inc's primary focus?

TG Therapeutics Inc is focused on developing and commercializing novel treatments for B-cell diseases, particularly hematologic malignancies and autoimmune disorders such as multiple sclerosis.

What is unique about their lead product candidate?

Their lead candidate is a glycoengineered monoclonal antibody designed to target a unique epitope on the CD20 antigen, enabling efficient B-cell depletion while aiming for improved safety and efficacy profiles.

Which therapeutic areas does TG Therapeutics primarily target?

The company targets B-cell malignancies and autoimmune diseases, emphasizing areas where novel antibody therapies and inhibitors can address unmet clinical needs.

How does TG Therapeutics differentiate itself from competitors?

TG Therapeutics differentiates itself through advanced antibody engineering, a robust clinical pipeline, and a strategic approach that integrates research, development, and commercialization with a focus on precision medicine.

What other products or technologies are in the company’s pipeline?

In addition to its established monoclonal antibody candidate, the company is developing an orally available PI3K delta inhibitor and has ongoing preclinical programs targeting additional immune pathways, thereby diversifying its pipeline.

Where is TG Therapeutics headquartered and traded?

TG Therapeutics is headquartered in New York City and its shares are traded on the NASDAQ under the ticker symbol TGTX.

What role do clinical trials play in TG Therapeutics' strategy?

Clinical trials are central to the company’s strategy, providing data that validate the safety, efficacy, and overall potential of its therapeutic candidates in addressing serious B-cell related diseases.

How does TG Therapeutics enhance trust and transparency?

The company emphasizes rigorous data collection and transparent communication of its clinical trial results, safety profiles, and developmental milestones to build trust with healthcare professionals, researchers, and investors.

Tg Therapeutics Inc

NASDAQ:TGTX

TGTX Rankings

#1781 Ranked by Market Cap

N/A Ranked by Dividends

TGTX Stock Data

Market Cap 5.56B

Float 143.29M

Insiders Ownership 9.74%

Institutions Ownership 63.27%

Short Percent 15.22%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City NEW YORK